Knockdown of PREX2a inhibits the malignant phenotype of osteosarcoma cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Osteosarcoma (OS) is a primary bone malignancy with significant metastatic potential.
• The role of Phosphatidylinositol‑3,4,5‑trisphosphate‑dependent Rac exchange factor 2a (PREX2a) in OS pathogenesis is not well understood.
• PREX2a is known to regulate Rac and influence Phosphatase and Tensin homolog deleted on chromosome ten (PTEN) and Phosphoinositide 3‑kinase (PI3K) signaling.

Purpose of the Study:

• To investigate the role of PREX2a in osteosarcoma (OS) cell proliferation, invasion, and migration.
• To elucidate the underlying molecular mechanisms involving PTEN and PI3K signaling pathways.
• To determine if PREX2a acts as an oncogene in OS.

Main Methods:

• Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blotting to assess PREX2a mRNA and protein levels.
• MTT assays to evaluate cell proliferation rates.
• Transwell and wound healing assays to measure cell invasion and migration capabilities.
• Analysis of PTEN activity and PI3K signaling pathway activation.

Main Results:

• PREX2a was significantly upregulated in OS cell lines compared to normal osteoblast cells.
• Knockdown of PREX2a inhibited OS cell proliferation, invasion, and migration, partly by reducing matrix metalloproteinase (MMP)2 and MMP9 expression.
• Overexpression of PREX2a promoted OS cell proliferation, invasion, and migration.
• PREX2a knockdown led to reduced PI3K signaling and increased PTEN activity, while PREX2a upregulation showed the opposite effect.

Conclusions:

• PREX2a is upregulated in osteosarcoma and promotes tumor progression.
• PREX2a functions as an oncogene in OS by inhibiting PTEN activity and activating PI3K signaling.
• Targeting PREX2a may represent a potential therapeutic strategy for osteosarcoma.